Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study
University of Miami · Oregon Health & Science University · +7 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
249
total citations
- FWCI
- 53.96
- Percentile
- 100%
- References
- 45
Citations per year
Authors
55Topics & keywords
Topics
Keywords
- Myasthenia gravis
- Medicine
- Tolerability
- Internal medicine
- Adverse effect
- Chimeric antigen receptor
- Antigen
- Autoantibody
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- MGMyasthenia Gravis Foundation of America
- AAstraZeneca
- SSanofi
- MDMuscular Dystrophy Association
- APAlexion Pharmaceuticals
- RPRegeneron Pharmaceuticals
- VTValerion Therapeutics
- ZZogenix
- AAcceleron
- AAveXis
- STSarepta Therapeutics
- ATAmicus Therapeutics
- MAMyositis Association
- ATAudentes Therapeutics
- AArgenx
- APAstellas Pharma
- GGrifols
- NINational Institutes of HealthAwards: R25NS088248, NS115426–01A1, MG-001
- CFCenters for Disease Control and Prevention
- STSpark Therapeutics
- NINational Institute of Neurological Disorders and Stroke
- UPUCB Pharma